“The FDA has issued a nationwide recall of lisdexamfetamine capsules.”

That sentence in Newsweek magazine should have triggered alerts, guidance, and coordinated response. Instead, the silence from pediatric leadership has been deafening. Newsweek turned to the FDA and the American Academy of Family Physicians. Where are the leadership of the American Academy of Pediatrics (AAP) and the Society for Developmental and Behavioral Pediatrics? Silent. Why?

The recall that should have sparked action

In November 2025, the FDA classified a nationwide recall of lisdexamfetamine dimesylate capsules (commonly known as Vyvanse) as a Class II recall. This means the product may cause temporary or medically reversible adverse health consequences. The manufacturer, Sun Pharmaceutical Industries, initiated the recall. The FDA confirmed the risk.

This isn’t a fringe medication. Lisdexamfetamine is a first-line treatment for ADHD, prescribed to millions of children and adults. It anchors school routines, family stability, and clinical care. A recall of this magnitude should have triggered immediate alerts from the American Academy of Pediatrics (AAP) and the Society for Developmental and Behavioral Pediatrics (SDBP).

But they said nothing.

Clinical fallout: risk without guidance

Families managing ADHD now face:

• Pharmacy confusion
• Abrupt medication changes
• Uncertainty about safety and supply
• Silence from the very institutions meant to guide them

Clinicians must now navigate risk without a compass. They must explain a recall without institutional backing. They must reassure families without data, context, or coordinated messaging. This isn’t just a missed opportunity. It’s a dereliction of duty.

I was targeted; I resisted

I remember the pitch while I was Director of Research at the Arizona Child Study Center. A pharmaceutical rep (proud of her basketball grit) spoke glowingly about Adderall. She knew the game. She knew Dianna Taurasi from UCONN. She also knew how to sell.

When Vyvanse entered the market, she flipped the script. Suddenly, Adderall became unreliable. She lambasted its pharmacokinetics and pushed Vyvanse as the superior solution. She didn’t cite data. She performed allegiance.

I had already seen Adderall’s variability firsthand. I knew its duration of action could be erratic. But I also knew the sales pitch wasn’t about science. It was about market share.

I resisted. I didn’t take the dinners. I didn’t accept the gifts. I didn’t let Big Pharma choreograph my prescribing habits.

Many of my colleagues did. They accepted the meals, the branded pens, the conference perks. They let the marketing shape their clinical decisions. Now, when a nationwide recall hits, they stay silent. They don’t warn families. They don’t challenge the manufacturers. They don’t speak, because they’ve already been bought.

The AAFP still holds the line. As for the AAP and SDBP, their continued silence raises difficult questions about the potential influence of industry funding, leaving families to navigate these risks alone.

The broader collapse: measles, misinformation, and institutional retreat

This recall arrives amid a broader collapse in pediatric public health. The CDC recently revised its vaccine safety language, stating that “the claim ‘vaccines do not cause autism’ is not evidence-based because studies have not ruled out the possibility.” This rhetorical retreat mirrors the same institutional cowardice.

Meanwhile, the U.S. is on the brink of losing its measles elimination status, just as Canada did last week. The outbreak that began in Texas in January shows no signs of slowing. If it continues into January 2026, measles will be reclassified as endemic.

This year alone:

• Over 1,700 measles cases
• 45 outbreaks
• 211 hospitalizations, including 100 children under age five
• Three deaths

Whooping cough cases are also surging. This isn’t just a public health failure. It’s a collapse of coordinated care, fueled by rhetorical sabotage and institutional retreat.

The cost of silence

As a developmental pediatrician, I’ve watched families unravel under the weight of uncertainty. As a historian, I’ve documented what happens when institutions retreat from their mission. When pediatric leadership refuses to speak, others fill the void, with misinformation, fear, and opportunism.

We cannot afford that void. Not now. Not with ADHD care under siege. Not with measles returning. Not with trust in medicine hanging by a thread.

Ronald L. Lindsay is a retired developmental-behavioral pediatrician whose career spanned military service, academic leadership, and public health reform. His professional trajectory, detailed on LinkedIn, reflects a lifelong commitment to advancing neurodevelopmental science and equitable systems of care.

Dr. Lindsay’s research has appeared in leading journals, including The New England Journal of Medicine, The American Journal of Psychiatry, Archives of General Psychiatry, The Journal of Child and Adolescent Psychopharmacology, and Clinical Pediatrics. His NIH-funded work with the Research Units on Pediatric Psychopharmacology (RUPP) Network helped define evidence-based approaches to autism and related developmental disorders.

As medical director of the Nisonger Center at The Ohio State University, he led the Leadership Education in Neurodevelopmental and Related Disabilities (LEND) Program, training future leaders in interdisciplinary care. His Ohio Rural DBP Clinic Initiative earned national recognition for expanding access in underserved counties, and at Madigan Army Medical Center, he founded Joint Base Lewis-McChord (JBLM) CARES, a $10 million autism resource center for military families.

Dr. Lindsay’s scholarship, profiled on ResearchGate and Doximity, extends across seventeen peer-reviewed articles, eleven book chapters, and forty-five invited lectures, as well as contributions to major academic publishers such as Oxford University Press and McGraw-Hill. His memoir-in-progress, The Quiet Architect, threads testimony, resistance, and civic duty into a reckoning with systems retreat.